Emraclidine

Generic Name: Emraclidine

Clinical Trials

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Emraclidine
Drug: Esomeprazole

First Posted Date: 2024-04-15

Last Posted Date: 2024-07-24

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 20

Registration Number: NCT06366243

Locations: 🇺🇸
Dilworth, Minnesota, Dilworth, Minnesota, United States

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Emraclidine

First Posted Date: 2024-03-08

Last Posted Date: 2024-05-02

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 8

Registration Number: NCT06301971

Locations: 🇺🇸
Austin, Texas, Austin, Texas, United States

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Emraclidine
Drug: Itraconazole
Drug: Carbamazepine
Drug: Metformin

First Posted Date: 2023-07-28

Last Posted Date: 2024-04-02

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 60

Registration Number: NCT05965219

Locations: 🇺🇸
Overland Park, Kansas, Overland Park, Kansas, United States

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Emraclidine

First Posted Date: 2023-07-11

Last Posted Date: 2025-04-04

Lead Sponsor: AbbVie

Target Recruit Count: 58

Registration Number: NCT05940402

Locations: 🇺🇸
Tustin, California, Tustin, California, United States
🇺🇸
Miami, Florida, Miami, Florida, United States
🇺🇸
Orlando, Florida, Orlando, Florida, United States

and more 1 locations

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Emraclidine

First Posted Date: 2023-07-07

Last Posted Date: 2025-04-04

Lead Sponsor: AbbVie

Target Recruit Count: 38

Registration Number: NCT05935033

Locations: 🇺🇸
Miami, Florida, Miami, Florida, United States
🇺🇸
Orlando, Florida, Orlando, Florida, United States
🇺🇸
San Antonio, Texas, San Antonio, Texas, United States

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Emraclidine

First Posted Date: 2023-06-23

Last Posted Date: 2023-11-24

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 16

Registration Number: NCT05915546

Locations: 🇺🇸
Dilworth, Minnesota, Dilworth, Minnesota, United States

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease Dementia
Healthy Participants

Interventions: Drug: Emraclidine
Drug: Placebo

First Posted Date: 2022-12-09

Last Posted Date: 2025-05-02

Lead Sponsor: AbbVie

Target Recruit Count: 17

Registration Number: NCT05644977

Locations: 🇺🇸
Cypress, California, Cypress, California, United States
🇺🇸
San Diego, California, San Diego, California, United States
🇺🇸
Hialeah, Florida, Hialeah, Florida, United States

and more 8 locations

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

Phase 1

Completed

Conditions: Blood Pressure
Schizophrenia

Interventions: Drug: CVL-231

First Posted Date: 2022-02-18

Last Posted Date: 2022-12-14

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 151

Registration Number: NCT05245539

Locations: 🇺🇸
Uptown Research Institute LLC, Chicago, Illinois, United States
🇺🇸
Hassman Research Institute - Apex - PPDS, Marlton, New Jersey, United States
🇺🇸
Woodland International Research Group LLC - ERG - PPDS, Little Rock, Arkansas, United States

and more 5 locations

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: CVL-231

First Posted Date: 2021-03-08

Last Posted Date: 2023-07-27

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 15

Registration Number: NCT04787302

Locations: 🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸
Massachusetts General Hospital Translational and Clinical Research Centers, Boston, Massachusetts, United States

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Matching Placebo
Drug: CVL-231

First Posted Date: 2019-10-23

Last Posted Date: 2021-07-02

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 130

Registration Number: NCT04136873

Locations: 🇺🇸
Synergy San Diego, Lemon Grove, California, United States
🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States
🇺🇸
Pillar Clinical Research, Bentonville, Arkansas, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy